Literature DB >> 20139058

Perivascular epithelioid cell tumor (PEComa) of the uterus with aggressive behavior at presentation.

Jing-Lan Liu1, Yueh-Min Lin, Ming-Chieh Lin, Kun-Tu Yeh, Jui-Chang Hsu, Chih-Jung Chin.   

Abstract

Perivascular epithelioid cell tumor (PEComa) is a rare mesenchymal tumor composed of histologically and immunohistochemically distinctive perivascular epithelioid cells (PECs). Both benign and malignant tumors have been identified, but the criteria for diagnosis of malignancy have not been fully established due to the rarity of the tumor. We report on a case of uterine PEComa in a 33-year old woman with lymph node metastasis at presentation. The tumor had the characteristic histologic features of PEComa with cytologic atypia, mitotic activity of 2/10 high power field (HPF), and necrosis; it exhibited immunopositivity for HMB-45, calponin and desmin and was negative for melan-A. The patient received neoadjuvant chemotherapy, debulking surgery and adjuvant chemotherapy. No evidence of recurrence or metastasis was apparent 8 months after surgery.

Entities:  

Mesh:

Year:  2009        PMID: 20139058     DOI: 10.1016/s1658-3876(09)50013-1

Source DB:  PubMed          Journal:  Hematol Oncol Stem Cell Ther


  4 in total

Review 1.  Perivascular epithelioid tumours (PEComas) of the gynaecological tract.

Authors:  Niamh Conlon; Robert A Soslow; Rajmohan Murali
Journal:  J Clin Pathol       Date:  2015-03-06       Impact factor: 3.411

2.  Perivascular Epithelioid Cell Tumour of the Uterus: a Case Report.

Authors:  G Nath Aswathy; P Rema; S Suchetha; J Sivaranjith; Dinesh Dhanya
Journal:  Indian J Surg Oncol       Date:  2020-06-20

Review 3.  Perivascular epithelioid cell tumors (PEComa) of the female genital tract: A challenging question for gynaecologic oncologist and pathologist.

Authors:  Angiolo Gadducci; Gian Franco Zannoni
Journal:  Gynecol Oncol Rep       Date:  2020-07-06

4.  A Retrospective Case Study of 13 Uterine Perivascular Epithelioid Cell Neoplasm (PEComa) Patients.

Authors:  Jiahui Gu; Wantong Wang; Shizhuo Wang
Journal:  Onco Targets Ther       Date:  2021-03-09       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.